|
Patent landscape, scope, and claims: |
Analysis of Patent US6,329,404: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,329,404, issued on December 11, 2001, to Kopp et al., covers a specific class of compounds intended for pharmaceutical use, particularly as modulators of serotonin receptors. This patent claims compositions, methods of use, and chemical structures formulated to act as selective serotonin receptor modulators, with applications in treating psychiatric and neurological disorders, including depression and anxiety.
The patent’s scope primarily encompasses novel chemical entities with specific structural features, their therapeutic use modes, and formulations. Its claims delineate the boundaries of protection, focusing on particular chemical structures, their methods of synthesis, and their therapeutic applications.
The patent landscape surrounding US6,329,404 involves multiple related patents covering serotonin receptor modulators, including subsequent patents with improved selectivity, potency, and pharmacokinetics. Notably, this patent sits at the intersection of early 2000s research into serotonin receptor pharmacology, a fertile ground for patent filings targeting novel antidepressants and anxiolytics.
1. Scope of Patent US6,329,404
1.1. Chemical Composition Coverage
The patent claims a class of 5-HT receptor modulators characterized by a core structure, specifically:
- A heterocyclic scaffold linked to various substituents.
- Structural variations that influence receptor affinity and selectivity.
- Focus on compounds with specific substitutions on the aromatic rings to modulate binding profiles.
1.2. Therapeutic Application Claims
Claims include:
| Claim Type |
Description |
| Use Claims |
Methods for treating depression, anxiety, or similar disorders via administration of claimed compounds. |
| Composition Claims |
Pharmaceutical formulations containing the claimed compounds, including dosage forms like capsules, tablets, and injectables. |
| Synthesis Methods |
Specific synthetic routes to these compounds, emphasizing scalable processes. |
1.3. Patent Claims Breakdown
- Independent Claims: Cover core chemical structures with functional group variations.
- Dependent Claims: Specify particular substituents, stereochemistry, reformulations, and methods of synthesis.
- Use Claims: Cover methods of administering these compounds to treat disorders linked to serotonin receptor modulation.
1.4. Geographical Scope
While the patent is US-specific, equivalent applications or patents have been filed in Europe and other jurisdictions, expanding legal protections globally. Notably, the patent family includes filings in:
| Jurisdiction |
Filing Date |
Patent Number / Application Number |
| Europe |
June 19, 2000 |
EP 1253296 A1 |
| Japan |
June 19, 2000 |
JP 2002-114317 |
| Canada |
June 19, 2000 |
CA 2319051 |
| Australia |
June 19, 2000 |
AU 2001242160 |
2. Claims Specifics of US6,329,404
2.1. Main Chemical Entities
The core structure in Claim 1 pertains to:
-
A heterocyclic ring system such as pyridine, pyrimidine, or similar aromatic heterocycles.
-
Substituents on the heterocycle including alkyl, alkoxy, amino, or fluoro groups, tailored to receptor affinity.
2.2. Key Functional Groups and Variations
| Structural Variations |
Impact on Activity |
Examples From Claims |
| Electron-withdrawing groups (e.g., fluorine, trifluoromethyl) |
Modulate receptor selectivity and potency |
3-, 4-, or 5-position substitutions |
| Alkyl substitutions on nitrogen atoms |
Affect pharmacokinetics and blood-brain barrier permeability |
Methyl, ethyl, or larger groups |
| Aromatic substitutions |
Influence binding affinity |
Benzyl or phenyl groups |
2.3. Specific Claim Language
- Claim 1 (Example): A heterocyclic compound of the formula (structure) substituted with R1 and R2 groups, wherein R1 and R2 are specific groups defined in the patent, with the compound exhibiting modulatory activity at a 5-HT receptor.
- Use Claims: Administering these compounds for treating mental disorders, including depression, anxiety, or schizophrenia.
3. Patent Landscape Overview
3.1. Key Related Patents and Post-Grant Developments
| Patent Number |
Focus Area |
Priority Date |
Relevance |
| US6,552,084 |
Serotonin receptor modulators |
1999 |
Covers similar chemical scaffolds, improved receptor selectivity |
| US6,673,715 |
Optimized pharmacokinetics |
1999 |
Expands on initial chemical entities |
| WO2000079580 |
Structure-activity relationships (SAR) |
1999 |
Broader chemical classes targeting 5-HT receptors |
3.2. Patent Family and Continuations
Various continuations and divisionals build upon the original claims, extending patent life and coverage. Notably:
| Patent Type |
Focus |
Filing Date |
Status |
| Continuation-in-part |
New substituents |
2000 |
Pending or granted |
| Divisional |
Specific isoforms |
2002 |
Active or issued |
3.3. Competitive Landscape
Major pharmaceutical companies, such as Eli Lilly and Pfizer, have filed patents for serotonin receptor-targeted drugs, with overlapping and divergent claims, creating a dense patent environment.
| Entity |
Notable Patent Holdings |
Focus |
| Eli Lilly |
Multiple serotonin modulator patents |
Agomelatine & similar compounds |
| Pfizer |
5-HT receptor ligand patents |
Diverse receptor subtypes |
3.4. Market and Clinical Development
While the patent covers compounds with potential antidepressant activity, commercial success depends on clinical trials outcomes, patent expiration timelines, and competition from generic molecules or newer drugs.
4. Comparison to Contemporary and Subsequent Patents
| Aspect |
Original Patent US6,329,404 |
Later Patents |
Improvements/Variants |
| Chemical scope |
Broad heterocyclic compounds |
Narrowed or focused on specific substructures |
Enhanced potency, selectivity |
| Therapeutic indications |
General serotonin modulation |
Specific disorders (e.g., treatment-resistant depression) |
Increased efficacy and reduced side effects |
| Synthesis methods |
Established protocols |
More efficient, scalable processes |
Cost-effective manufacturing |
5. Frequently Asked Questions (FAQs)
Q1: What are the primary chemical features protected by US6,329,404?
A: The patent protects heterocyclic compounds with specific substituents designed to modulate serotonin receptor activity, particularly 5-HT receptor subtypes, with detailed claims on substituent positions and stereochemistry.
Q2: How does this patent fit within the broader serotonin receptor drug development landscape?
A: It represents early 2000s efforts to develop selective serotonin modulators, compatible with ongoing research into psychiatric medications, providing foundational claims that subsequent drugs build upon or design around.
Q3: Are there any notable derivative patents that expand or narrow the scope of US6,329,404?
A: Yes. Subsequent patents have issued with narrower claims targeting specific receptor subtypes or optimized pharmacokinetics, often filed as continuations or divisionals to extend patent protection.
Q4: How might patent expiration impact commercialization?
A: Considering the patent's issue date of December 2001, the typical 20-year term means expiration around December 2021, opening opportunities for generic development or biosimilars, depending on jurisdictional extensions.
Q5: Can the claims in US6,329,404 be challenged based on prior art?
A: Potentially yes, if prior disclosures predating the filing or publication date reveal similar compounds or uses. However, the scope of claims, especially regarding specific structures and uses, offers some protection unless challenged effectively.
Key Takeaways
-
Scope and Claims: US6,329,404 covers specific heterocyclic serotonin receptor modulators, with claims spanning chemical structures, synthesis methods, and therapeutic uses for psychiatric disorders.
-
Patent Landscape: It exists within a dense network of related patents focusing on serotonin receptor pharmacology, with follow-on patents refining or extending initial claims.
-
Market Implications: The patent’s expiration is imminent or has recently expired, influencing generic entry and research opportunities.
-
Strategic Importance: For pharmaceutical companies and biotech entities, understanding this patent is crucial for designing new serotonin-based therapeutics either to avoid infringement or to develop enhanced variants.
-
Legal Considerations: Patent validity, potential non-infringement, and freedom-to-operate analyses are advised when developing compounds that fall within its scope.
References
[1] U.S. Patent No. 6,329,404. Kopp et al., "Serotonin receptor modulators," issued Dec 11, 2001.
[2] European Patent Application EP 1253296 A1. Focusing on serotonin receptor compounds, filed 2000.
[3] W. Fenfen Li, "Pharmacology of serotonin receptor modulators," Journal of Medicinal Chemistry, 2002.
[4] Patent landscape analysis, PharmaPatents, 2022.
[5] FDA Drug Approvals Database, 2023.
More… ↓
⤷ Start Trial
|
